You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.
Nov 22, 2010
Evive Completed F-627 Phase I Dosing in Australia
2010-11-22. Evive Biotech completed F-627 Phase I dosing in Australia. The primary objective of the study is to investigate the safety profile of F-627 in healthy volunteers. The secondary objective of the study is to evaluate the pharmacokinetics and pharmacodynamics (PK/PD) properties of F-627. F-627 is a recombinant G-CSF dimer, expressed in mammalian cells.
You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.
